| Dr5-selective trail variant dr5-b functionalized with tumor-penetrating irgd peptide for enhanced antitumor activity against glioblastoma AV Yagolovich, AA Isakova, AA Artykov, YV Vorontsova, DV Mazur, ... International Journal of Molecular Sciences 23 (20), 12687, 2022 | 6 | 2022 |
| Optimized heterologous expression and efficient purification of a new TRAIL-based antitumor fusion protein SRH–DR5-B with dual VEGFR2 and DR5 receptor specificity AV Yagolovich, AA Artykov, AA Isakova, YV Vorontsova, DA Dolgikh, ... International Journal of Molecular Sciences 23 (11), 5860, 2022 | 6 | 2022 |
| Application of an autoinduction strategy to optimize the heterologous production of an antitumor bispecific fusion protein based on the TRAIL receptor-selective mutant variant … A Isakova, A Artykov, Y Vorontsova, D Dolgikh, M Kirpichnikov, ... Molecular Biotechnology 65 (4), 581-589, 2023 | 3 | 2023 |
| Development of the hybrid antitumor bispecific protein DR5-B-iRGD A Yagolovich, A Artykov, A Isakova, E Vorontsova, L Kurbanova, ... FEBS OPEN BIO 12, 74-74, 2022 | | 2022 |
